During pregnancy, maternal pancreatic islets grow to match dynamic physiological demands, but the mechanisms regulating adaptive islet growth in this setting are poorly understood. Here we show that menin, a protein previously characterized as an endocrine tumor suppressor and transcriptional regulator, controls islet growth in pregnant mice. Pregnancy stimulated proliferation of maternal pancreatic islet b-cells that was accompanied by reduced islet levels of menin and its targets. Transgenic expression of menin in maternal b-cells prevented islet expansion and led to hyperglycemia and impaired glucose tolerance, hallmark features of gestational diabetes. Prolactin, a hormonal regulator of pregnancy, repressed islet menin levels and stimulated b-cell proliferation. These results expand our understanding of mechanisms underlying diabetes pathogenesis and reveal potential targets for therapy in diabetes.
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M aternal pancreatic islet expansion in rodents and humans (1) (2) (3) suggests that adaptive islet cell growth is a mechanism for ensuring metabolic balance in pregnancy, a physiological state marked by increased insulin demand. Descriptive studies with rats (2, 3) support the hypothesis that proliferation of insulinsecreting islet b-cells is the principal mechanism of b-cell expansion in pregnancy, but the molecular basis of facultative maternal b-cell proliferation is unknown. Moreover, it is unclear if impaired maternal b-cell proliferation leads to reduced insulin levels and gestational diabetes (4) .
To investigate the mechanisms controlling maternal islet expansion, we examined b-cell mass in pregnant C57Bl6 mice. We found that maternal b-cell mass increased by twofold ( fig. S1A ), accommodating increases in maternal body mass ( fig. S1B ). After parturition, maternal b-cell mass and body mass returned to prepartum levels (fig. S1, A and B). To assess maternal islet cell proliferation, we performed labeling studies with bromodeoxyuridine (BrdU). b-cell proliferation increased in pregnant mice until 15 days postcoitum (dpc) and then declined to prepartum levels ( Fig. 1 , A to C). Thus, maternal islet b-cell expansion and mass are dynamic in mice.
Hyperplasia of the maternal pituitary (5) and islets in pregnancy is reminiscent of endocrine proliferation in multiple endocrine neoplasia type 1 (MEN1), a human cancer syndrome characterized by synchronous tumors of the pituitary, endocrine pancreas, and parathyroid. Most MEN1 cases result from mutation of Men1, whose protein product is menin (6, 7) . In mice and humans, mutation and pathological Men1 loss promote neuroendocrine tumors, including islet b-cell tumors (7, 8) . Thus, we postulated that physiological changes in Men1 expression might regulate facultative maternal b-cell growth in pregnancy. Immunohistology, Western blotting, and real-time reverse transcription polymerase chain reaction (RT-PCR) studies of maternal islets isolated during gestation revealed that islet levels of Men1 mRNA and menin decreased in pregnancy (Fig. 1 , D to G), then increased to prepartum levels by 1 week after birth of the pups (Fig. 1, F and G) . By contrast, we did not detect changes in maternal islet levels of mRNA encoding mixed lineage leukemia-1 (MLL1), a protein that associates with menin (Fig. 1F) . Thus, attenuated Men1 expression corresponded with increased b-cell proliferation in maternal islets.
Menin functions in a histone methyltransferase protein complex containing MLL (9, 10) . This complex promotes trimethylation of histone H3 on lysine 4 (H3K4), an epigenetic mark associated with transcriptionally active chromatin. Menindependent histone methylation maintains expression of p27
Kip1 and p18 INK4C (hereafter, p27 and p18), which encode cyclin-dependent kinase (CDK) inhibitors that prevent islet proliferation (11) (12) (13) (14) . Consistent with our previous findings in islet tumors (11), reduced islet menin levels in pregnancy after 8 dpc were accompanied by reduced p27 and p18 mRNA and protein levels ( Fig. 1G and fig.  S1C ) and, as revealed by chromatin immunoprecipitation (ChIP), by decreased levels of menin and trimethyl H3K4 associated with p27 and p18 (Fig.  1H) . Thus, attenuated menin levels and function reduced pancreatic islet p27 and p18 expression in pregnant mice.
To determine whether adaptive maternal b-cell proliferation might require reduced Men1 expression, we generated mice that permitted conditionaland B). In islets isolated from male or virgin female bMen1 mice continuously exposed to Dox after 10 weeks of age, we detected increased levels of Men1, p27, and p18 mRNA. Thus, conditional induction of menin in b-cells stimulated expression of known menin-target genes. However, TREMen1 expression in male or virgin female bMen1 mice did not alter serum insulin or glucose control (fig. S2, C to E), indicating that TRE-Men1 expression alone did not disrupt b-cell function.
To assess the consequences of menin misexpression during pregnancy, we continuously exposed 10-week-old bMen1 females to Dox for 8 weeks, a period encompassing mating, gestation, and delivery. Western blot and RT-PCR analysis revealed that Men1 mRNA and menin levels were increased in islets from Dox-exposed pregnant bMen1 females compared to controls, and immunohistology confirmed that menin was increased in islet b-cells from bMen1 mothers (Fig. 2 , A to E, and fig. S2F ). p27 and p18 mRNA and protein in bMen1 islets also increased to levels indistinguishable from those in prepartum islets ( Fig. 2A and  fig. S2F ). By contrast, mRNAs encoding Insulin1 (Ins1), Insulin2 (Ins2), Glut2, and Pdx1, factors that govern b-cell function, were unchanged in bMen1 islets ( fig. S2G ). We measured glucose regulation, islet gene expression, and b-cell growth in female bMen1 mice starting at 10 weeks of age. Unlike age-matched pregnant controls or virgin bMen1 females exposed to Dox, pregnant bMen1 females exposed to Dox and fed ad libitum developed moderate hyperglycemia by 9 dpc, which worsened until delivery ( Fig. 2F and fig. S3 , A and B). Compared to controls, mean glucose levels in fasted bMen1 mothers on Dox were also significantly higher (Fig. 2G and fig. S3C ). Intraperitoneal glucose challenge similarly revealed impaired glucose tolerance in pregnant bMen1 females on Dox (Fig. 2G) . Consistent with these findings, serum insulin levels were reduced in pregnant bMen1 mice (Fig. 2H ). Other phenotypes, including body mass, litter size, and average birth weight of pups, were indistinguishable for bMen1 mothers and controls ( fig. S4 , A to C). In women with gestational diabetes, serum glucose concentration often returns to normal after delivery. Likewise in bMen1 mothers on Dox, blood glucose levels decreased after birth of the pups and were indistinguishable from those of control mothers (Fig. 2F) . Thus, bMen1 mice recapitulated features of human gestational diabetes. To investigate whether impaired insulin production or secretion might underlie hypoinsulinemia in bMen1 mice, we measured insulin content and secretion in isolated islets. Insulin content per islet cell was similar in pregnant bMen1 and control mice ( fig. S4D) . Likewise, insulin secretion by bMen1 islets after stimulation with glucose or arginine (fig. S4, E and F) was indistinguishable from that of controls. To determine if gestational hypoinsulinemia and hyperglycemia in bMen1 mice reflected impaired b-cell expansion, we assessed the pancreata of pregnant bMen1 and control mice. In Dox-treated pregnant bMen1 mice at the end of gestation, b-cell mass was significantly reduced compared to pregnant controls and appeared indistinguishable from b-cell mass in prepartum bMen1 mice (Fig. 2I) . In pregnant bMen1 mice, BrdU studies revealed reduced b-cell proliferation at 17 dpc (Fig. 2, J to  L) . Thus, gestational reduction of menin, p27, and p18 levels was prevented in bMen1 islets, leading to impaired b-cell expansion. Moreover, we did not detect differences in islet cell apoptosis in bMen1 and control littermate mice ( fig. S3G) , suggesting that reduced b-cell mass in bMen1 mice did not result from cell death. Collectively, these findings suggest that attenuation of maternal islet menin levels permits adaptive b-cell expansion in pregnancy.
Prolactin and placental lactogens are hormonal regulators of pregnancy that stimulate b-cell proliferation in rodent and human islets (17) (18) (19) , but the molecular basis for their mitogenic effect is unknown. We investigated if prolactin signaling regulates Men1 in b-cells. Lactogenic hormones stimulate phosphorylation and nuclear accumulation of signal transducer and activator of transcription 5 (STAT5), which induces expression of targets like Bcl6 (20) . In islets from pregnant mice, nuclear STAT5 accumulated in b-cells (Fig. 3, A and B) , and levels of phospho-STAT5 and STAT5 occupancy at consensus STAT5 binding sequences (21) in Bcl6 increased (Fig. 3C and fig. S5A ). Bcl6 mRNA and protein content increased (Fig. 3C and  fig. S5B ), and ChIP revealed direct association of Bcl6, a transcriptional repressor (21, 22) , with Men1 during pregnancy (Fig. 3D) . Misexpression of Bcl6 in MIN6 cells, a murine insulinoma-derived b-cell line responsive to normal growth cues (11, 23) , was sufficient to reduce expression of endogenous Men1, p18, and p27 mRNA (fig. S5C) . Moreover, Bcl6 expression reduced transcription of Men1- , and p27 loci in islets isolated from nonpregnant, pregnant, postpartum day 4, and postpartum day 21 mice. Primer pair 2 (PP2) for Men1 has been described previously (7) . (E and F) Real-time RT-PCR analysis of Men1, p18, and p27 (E) or Bcl6 mRNA levels (F) in islets exposed to prolactin (black), vehicle (white), or to both prolactin and progesterone (gray) (n = 3 independent experiments). Real-time RT-PCR analysis of Bcl6 (G) or Men1, p18, and p27 mRNA levels (H) in islets from prolactin-infused (black) and control mice (white). (I) Quantification of BrdU incorporation by islet b-cells in prolactin-infused (black) or control mice (white) (n = 8 mice per treatment). *P < 0.05, **P < 0.01, ***P < 0.001. luciferase reporters harboring consensus Bcl6 binding sequences ( fig. S5, D and E) . Thus, Bcl6 directly associated with and repressed Men1 transcription in b-cells. Previous studies have shown that steroids like progesterone and dexamethasone can inhibit the mitogenic effects of prolactin on b-cells (24), but the underlying mechanism is unknown. Simultaneous exposure of isolated mouse islets to prolactin and progesterone attenuated changes in Men1, p18, p27, and Bcl6 expression provoked by prolactin alone (Fig. 3, E and F) . Thus, multiple hormonal inputs likely regulate b-cell Men1 expression. Bcl6-dependent changes in Men1, p18, and p27 expression provoked by prolactin in MIN6 cells or in cultured human islets (figs. S6 to S8) corroborated these findings and showed that Men1 regulation by lactogen signaling is evolutionarily conserved. To test if lactogen signaling was sufficient to reduce Men1 expression and increase b-cell proliferation in vivo, we transplanted mice with osmotic micropumps to deliver prolactin for 6 days (25). Compared with islets from vehicle-infused controls, islets from prolactin-infused mice had a fourfold increase in Bcl6 expression, a 50% reduction of Men1, p18, and p27 mRNA, and a 2.5-fold increase of BrdU incorporation by b-cells (Fig. 3, G to I) . Thus, short-term prolactin infusion was sufficient to reduce Men1 expression in vivo and to stimulate proliferation of adult islet b-cells. Additional studies are needed to determine if lactogenic hormone regulation of Men1 governs other features that affect bcell expansion, such as b-cell size and survival (26) .
To determine if menin might regulate adaptive bcell expansion in obesity, another common physiological state that stimulates adaptive islet expansion, we measured islet menin levels in A y mice, a wellcharacterized model of hyperphagic obesity [reviewed in (27) ]. At 3 months, when A y mice are obese but normoglycemic (Fig. 4, A and B) , A y islet levels of Men1 mRNA, menin, and p27 and p18 mRNA and protein were reduced compared to islets from wild-type controls (Fig. 4, C to E) . These results suggest that in obesity, menin attenuation regulates adaptive b-cell proliferation.
Studies of endocrine neoplasias in MEN1 syndrome and other cancers have defined menin roles solely in the context of tumor pathogenesis. Our work expands this view, showing that menin functions as a physiological regulator of adaptive b-cell expansion in pregnancy and possibly other common states linked to type 2 diabetes, such as obesity. We speculate that menin may integrate b-cell growth signals in physiological islet expansion, controlling dynamic histone modifications that govern b-cell fate and proliferation. Menin-independent control of maternal b-cell expansion is not excluded by our study, and investigating the role of other islet tumor suppressors, like von Hippel-Lindau protein (28) , in physiological b-cell expansion might be fruitful. Our finding that Men1 expression is regulated by prolactin and progesterone raises the possibility that defects in signaling pathways regulated by lactogenic or steroid hormones might underlie specific forms of type 2 diabetes, including gestational diabetes, and endocrine neoplasias linked to Men1 inactivation, including carcinoid and insulinoma (7). Our work also suggests that manipulation of regulators, cofactors, and targets of menin might be a therapeutic strategy for expanding functional pancreatic islets in diabetes.
